Structural, Molecular, and Functional Alterations of the Blood-Brain Barrier during Epileptogenesis and Epilepsy: A Cause, Consequence, or Both?

Wolfgang Löscher, Alon Friedman
Author Information
  1. Wolfgang Löscher: Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine Hannover, 30559 Hannover, Germany. ORCID
  2. Alon Friedman: Departments of Physiology and Cell Biology, Brain and Cognitive Sciences, Zlowotski Center for Neuroscience, Ben-Gurion University of the Negev, Beer-Sheva 8410501, Israel.

Abstract

The blood-brain barrier (BBB) is a dynamic, highly selective barrier primarily formed by endothelial cells connected by tight junctions that separate the circulating blood from the brain extracellular fluid. The endothelial cells lining the brain microvessels are under the inductive influence of neighboring cell types, including astrocytes and pericytes. In addition to the anatomical characteristics of the BBB, various specific transport systems, enzymes and receptors regulate molecular and cellular traffic across the BBB. While the intact BBB prevents many macromolecules and immune cells from entering the brain, following epileptogenic brain insults the BBB changes its properties. Among BBB alterations, albumin extravasation and diapedesis of leucocytes from blood into brain parenchyma occur, inducing or contributing to epileptogenesis. Furthermore, seizures themselves may modulate BBB functions, permitting albumin extravasation, leading to activation of astrocytes and the innate immune system, and eventually modifications of neuronal networks. BBB alterations following seizures are not necessarily associated with enhanced drug penetration into the brain. Increased expression of multidrug efflux transporters such as P-glycoprotein likely act as a 'second line defense' mechanism to protect the brain from toxins. A better understanding of the complex alterations in BBB structure and function following seizures and in epilepsy may lead to novel therapeutic interventions allowing the prevention and treatment of epilepsy as well as other detrimental neuro-psychiatric sequelae of brain injury.

Keywords

References

  1. Drug Discov Today. 2007 Jan;12(1-2):54-61 [PMID: 17198973]
  2. Semin Cell Dev Biol. 2015 Feb;38:26-34 [PMID: 25444846]
  3. Proc Natl Acad Sci U S A. 2016 Sep 20;113(38):E5665-74 [PMID: 27601660]
  4. Brain. 2007 Jul;130(Pt 7):1942-56 [PMID: 17533168]
  5. Curr Pharm Des. 2011;17(26):2808-28 [PMID: 21827408]
  6. Epilepsia. 2018 Jan;59(1):37-66 [PMID: 29247482]
  7. Expert Opin Drug Deliv. 2018 Sep;15(9):915-925 [PMID: 30169981]
  8. J Neurol Neurosurg Psychiatry. 2008 Jul;79(7):774-7 [PMID: 17991703]
  9. Brain Pathol. 2007 Apr;17(2):243-50 [PMID: 17388955]
  10. Br J Hosp Med. 1991 Jan;45(1):32-4 [PMID: 2009437]
  11. Mol Neurobiol. 2019 Mar;56(3):1825-1840 [PMID: 29934763]
  12. J Comput Assist Tomogr. 1989 Sep-Oct;13(5):889-92 [PMID: 2506256]
  13. Neuropharmacology. 2009 Apr;56(5):849-55 [PMID: 19371577]
  14. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Oct 3;79(Pt A):15-18 [PMID: 28189704]
  15. Neurobiol Dis. 2010 Jan;37(1):13-25 [PMID: 19664713]
  16. JAMA Neurol. 2015 Mar;72(3):355-62 [PMID: 25599342]
  17. Epilepsia. 1970 Mar;11(1):73-80 [PMID: 4987162]
  18. Sci Rep. 2017 Aug 9;7(1):7711 [PMID: 28794441]
  19. Semin Cell Dev Biol. 2015 Feb;38:35-42 [PMID: 25444848]
  20. Front Neurol. 2017 Jul 06;8:301 [PMID: 28729850]
  21. Neurotherapeutics. 2009 Apr;6(2):344-51 [PMID: 19332329]
  22. Neurobiol Dis. 2006 Oct;24(1):202-11 [PMID: 16928449]
  23. Mol Psychiatry. 2018 Nov;23(11):2156-2166 [PMID: 28993710]
  24. J Comp Neurol. 1956 Dec;106(2):363-70 [PMID: 13416398]
  25. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr. 1955;193(1):68-77 [PMID: 14388746]
  26. J Neurosci. 2009 Jul 15;29(28):8927-35 [PMID: 19605630]
  27. Seizure. 2011 Jun;20(5):395-401 [PMID: 21315622]
  28. Adv Drug Deliv Rev. 2020;165-166:1-14 [PMID: 31790711]
  29. Neurobiol Dis. 2018 May;113:70-81 [PMID: 29432809]
  30. eNeuro. 2018 May 30;5(3): [PMID: 29854942]
  31. Nat Rev Drug Discov. 2013 Oct;12(10):757-76 [PMID: 24052047]
  32. Neuroscientist. 2013 Jun;19(3):304-12 [PMID: 23072899]
  33. Epilepsy Res. 2009 Aug;85(2-3):142-9 [PMID: 19362806]
  34. Novartis Found Symp. 2002;243:38-47; discussion 47-53, 180-5 [PMID: 11990780]
  35. Brain Res. 2010 Apr 22;1326:114-27 [PMID: 20197061]
  36. J Neurosci. 2018 May 2;38(18):4301-4315 [PMID: 29632167]
  37. Neuropharmacology. 1978 Aug;17(8):637-42 [PMID: 358007]
  38. Neuropharmacology. 2008 May;54(6):1006-16 [PMID: 18394657]
  39. Seizure. 2011 Jun;20(5):376-82 [PMID: 21514852]
  40. Adv Drug Deliv Rev. 2012 Jul;64(10):930-42 [PMID: 22197850]
  41. Neuroreport. 2002 Jan 21;13(1):167-71 [PMID: 11924882]
  42. Ann Neurol. 2014 Jun;75(6):864-75 [PMID: 24659129]
  43. Acta Neuropathol. 2016 Sep;132(3):317-38 [PMID: 27522506]
  44. Expert Rev Neurother. 2014 Dec;14(12):1365-75 [PMID: 25346269]
  45. Epilepsia. 2012 Nov;53(11):1877-86 [PMID: 22905812]
  46. J Mol Neurosci. 2007 Sep;33(1):32-41 [PMID: 17901543]
  47. Horm Metab Res. 1997 Dec;29(12):614-21 [PMID: 9497898]
  48. Tissue Barriers. 2016 Jan 28;4(1):e1143544 [PMID: 27141424]
  49. Nat Med. 2008 Dec;14(12):1377-83 [PMID: 19029985]
  50. Glia. 2012 Aug;60(8):1251-7 [PMID: 22378298]
  51. Neuropharmacology. 2013 Jun;69:16-24 [PMID: 22521336]
  52. Radiology. 2017 Nov;285(2):546-554 [PMID: 28653860]
  53. Pharmacol Rev. 2008 Jun;60(2):196-209 [PMID: 18560012]
  54. Brain Res Bull. 2019 Jul;149:251-259 [PMID: 31077774]
  55. Epilepsia. 2006 Apr;47(4):681-94 [PMID: 16650134]
  56. J Biol Inorg Chem. 2001 Feb;6(2):196-200 [PMID: 11293414]
  57. J Inherit Metab Dis. 2013 May;36(3):437-49 [PMID: 23609350]
  58. Neuron. 2017 Sep 27;96(1):17-42 [PMID: 28957666]
  59. Nat Rev Neurosci. 2005 Aug;6(8):591-602 [PMID: 16025095]
  60. Cold Spring Harb Perspect Med. 2015 Mar 02;5(3):a022434 [PMID: 25732035]
  61. Neuropharmacology. 2010 Jun;58(7):1019-32 [PMID: 20080116]
  62. Lancet Neurol. 2013 Aug;12(8):777-85 [PMID: 23786896]
  63. Nat Med. 2017 Jun;23(6):678-680 [PMID: 28459436]
  64. Neurobiol Dis. 2004 Jun;16(1):1-13 [PMID: 15207256]
  65. J Neurol. 2005 Jan;252(1):42-6 [PMID: 15672209]
  66. Life Sci. 1980 Jul 21;27(3):239-43 [PMID: 6772908]
  67. Mol Pharmacol. 2008 May;73(5):1444-53 [PMID: 18094072]
  68. Epilepsia. 2010 Aug;51(8):1333-47 [PMID: 20477844]
  69. Epilepsia. 1995 Jan;36(1):1-6 [PMID: 8001500]
  70. J Neurochem. 2011 Apr;117(2):333-45 [PMID: 21291474]
  71. JAMA Neurol. 2016 Jan;73(1):13-4 [PMID: 26524294]
  72. Epilepsia. 2017 Mar;58(3):315-330 [PMID: 27883181]
  73. Nature. 2012 Aug 30;488(7413):675-9 [PMID: 22914092]
  74. Adv Neurol. 1986;44:787-812 [PMID: 3085437]
  75. Epilepsy Behav. 2013 Oct;29(1):150-4 [PMID: 23973639]
  76. Semin Immunopathol. 2010 Sep;32(3):275-87 [PMID: 20623286]
  77. Neurobiol Dis. 2013 Apr;52:204-18 [PMID: 23291193]
  78. Curr Drug Metab. 2011 Oct;12(8):742-9 [PMID: 21568937]
  79. Epilepsy Res. 2016 Oct;126:197-200 [PMID: 27513375]
  80. J Neurosci. 2016 Dec 7;36(49):12296-12298 [PMID: 27927949]
  81. Neurobiol Dis. 2016 Jul;91:155-65 [PMID: 26972679]
  82. Brain. 2018 Oct 1;141(10):2952-2965 [PMID: 30239618]
  83. Clin Sci (Lond). 2018 Feb 8;132(3):361-374 [PMID: 29439117]
  84. J Cell Mol Med. 2009 Jul;13(7):1211-20 [PMID: 19538472]
  85. Nat Neurosci. 2017 Feb;20(2):136-144 [PMID: 28092660]
  86. Adv Neurol. 1999;79:845-62 [PMID: 10514868]
  87. Curr Pharm Des. 2014;20(10):1487-98 [PMID: 23789956]
  88. J Neurosci. 2009 Aug 26;29(34):10588-99 [PMID: 19710312]
  89. Prog Neurobiol. 2005 May;76(1):22-76 [PMID: 16011870]
  90. Proc Natl Acad Sci U S A. 2018 Sep 18;115(38):E8929-E8938 [PMID: 30181265]
  91. Neuropharmacology. 2015 Jun;93:7-14 [PMID: 25645391]
  92. J Neurosci. 2011 Mar 16;31(11):4037-50 [PMID: 21411646]
  93. Neurobiol Dis. 2015 Jun;78:115-25 [PMID: 25836421]
  94. Brain Res Brain Res Rev. 2004 Mar;44(2-3):141-53 [PMID: 15003390]
  95. Brain. 2012 Oct;135(Pt 10):3115-33 [PMID: 22750659]
  96. Epilepsy Behav. 2014 Aug;37:59-70 [PMID: 24980390]
  97. Nat Med. 2013 Dec;19(12):1584-96 [PMID: 24309662]
  98. Am J Cancer Res. 2016 Aug 01;6(8):1583-98 [PMID: 27648351]
  99. Neuropharmacology. 2011 Oct-Nov;61(5-6):909-17 [PMID: 21736886]
  100. Epilepsy Res. 2008 Feb;78(2-3):235-9 [PMID: 18178061]
  101. J Neurosci. 2016 Jul 20;36(29):7727-39 [PMID: 27445149]
  102. Brain. 2007 Feb;130(Pt 2):535-47 [PMID: 17121744]
  103. Epilepsia Open. 2018 Jul 16;3(Suppl Suppl 2):133-142 [PMID: 30564772]
  104. Epilepsia. 2019 Feb;60(2):322-336 [PMID: 30609012]
  105. Epilepsia. 2008;49 Suppl 2:3-12 [PMID: 18226167]
  106. Nat Rev Neurosci. 2014 May;15(5):300-12 [PMID: 24713688]
  107. Neurosurgery. 2019 Jul 1;85(1):E4-E15 [PMID: 30407567]
  108. Epilepsia. 2011 Apr;52(4):657-78 [PMID: 21426333]
  109. Epilepsia. 2009 Apr;50(4):664-77 [PMID: 19175391]
  110. Brain. 2017 Jun 1;140(6):1692-1705 [PMID: 28444141]
  111. Epilepsia. 2007 Apr;48(4):732-42 [PMID: 17319915]
  112. Epilepsia. 2014 Aug;55(8):1255-63 [PMID: 24995798]
  113. J Leukoc Biol. 2011 Apr;89(4):539-56 [PMID: 21169520]
  114. Epilepsy Res. 2016 Oct;126:157-84 [PMID: 27505294]
  115. Epilepsy Res. 2014 Nov;108(9):1642-51 [PMID: 25223728]

MeSH Term

ATP Binding Cassette Transporter, Subfamily B, Member 1
Albumins
Animals
Anticonvulsants
Blood-Brain Barrier
Epilepsy
Humans
Tight Junctions

Chemicals

ATP Binding Cassette Transporter, Subfamily B, Member 1
Albumins
Anticonvulsants

Word Cloud

Created with Highcharts 10.0.0BBBbraincellsfollowingalterationsalbuminseizuresbarrierendothelialtightjunctionsbloodastrocytesimmuneextravasationepileptogenesismayepilepsyblood-braindynamichighlyselectiveprimarilyformedconnectedseparatecirculatingextracellularfluidliningmicrovesselsinductiveinfluenceneighboringcelltypesincludingpericytesadditionanatomicalcharacteristicsvariousspecifictransportsystemsenzymesreceptorsregulatemolecularcellulartrafficacrossintactpreventsmanymacromoleculesenteringepileptogenicinsultschangespropertiesAmongdiapedesisleucocytesparenchymaoccurinducingcontributingFurthermoremodulatefunctionspermittingleadingactivationinnatesystemeventuallymodificationsneuronalnetworksnecessarilyassociatedenhanceddrugpenetrationIncreasedexpressionmultidrugeffluxtransportersP-glycoproteinlikelyact'secondlinedefense'mechanismprotecttoxinsbetterunderstandingcomplexstructurefunctionleadnoveltherapeuticinterventionsallowingpreventiontreatmentwelldetrimentalneuro-psychiatricsequelaeinjuryStructuralMolecularFunctionalAlterationsBlood-BrainBarrierEpileptogenesisEpilepsy:CauseConsequenceBoth?P-glycoproteinantiepilepticdrugs

Similar Articles

Cited By